| Peginterferon plus adefovir versus either drug alone for hepatitis delta H Wedemeyer, C Yurdaydìn, GN Dalekos, A Erhardt, Y Çakaloğlu, ... New England Journal of Medicine 364 (4), 322-331, 2011 | 525 | 2011 |
| Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience HL Tillmann, J Hadem, L Leifeld, K Zachou, A Canbay, C Eisenbach, ... Journal of viral hepatitis 13 (4), 256-263, 2006 | 319 | 2006 |
| Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta B Heidrich, C Yurdaydın, G Kabacam, BA Ratsch, K Zachou, B Bremer, ... Hepatology 60 (1), 87-97, 2014 | 312 | 2014 |
| Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics NK Gatselis, K Zachou, GK Koukoulis, GN Dalekos World journal of gastroenterology: WJG 21 (1), 60, 2015 | 254 | 2015 |
| autoimmune hepatitis–current management and challenges K Zachou, P Muratori, GK Koukoulis, A Granito, N Gatselis, A Fabbri, ... Alimentary pharmacology & therapeutics 38 (8), 887-913, 2013 | 239 | 2013 |
| Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of … K Zachou, N Gatselis, G Papadamou, EI Rigopoulou, GN Dalekos Journal of hepatology 55 (3), 636-646, 2011 | 221 | 2011 |
| Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease K Zachou, E Rigopoulou, GN Dalekos Journal of autoimmune diseases 1, 1-17, 2004 | 212 | 2004 |
| Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis EI Rigopoulou, ET Davies, A Pares, K Zachou, C Liaskos, DP Bogdanos, ... Gut 54 (4), 528-532, 2005 | 163 | 2005 |
| Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview GN Dalekos, K Zachou, C Liaskos, N Gatselis European journal of internal medicine 13 (5), 293-303, 2002 | 163 | 2002 |
| Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis K Zachou, C Yurdaydin, U Drebber, GN Dalekos, A Erhardt, Y Cakaloglu, ... Liver International 30 (3), 430-437, 2010 | 143 | 2010 |
| A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis K Zachou, NK Gatselis, P Arvaniti, S Gabeta, EI Rigopoulou, ... Alimentary pharmacology & therapeutics 43 (10), 1035-1047, 2016 | 112 | 2016 |
| Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? HL Tillmann, K Zachou, GN Dalekos Liver International 32 (4), 544-553, 2012 | 103 | 2012 |
| Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? NK Gatselis, K Zachou, P Papamichalis, GK Koukoulis, S Gabeta, ... Digestive and liver disease 42 (11), 807-812, 2010 | 99 | 2010 |
| Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity KG Oikonomou, K Zachou, GN Dalekos Autoimmunity reviews 10 (7), 389-396, 2011 | 98 | 2011 |
| Anti‐cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2‐glycoprotein I cofactor or features of antiphospholipid syndrome K Zachou, C Liaskos, DK Christodoulou, M Kardasi, G Papadamou, ... European journal of clinical investigation 33 (2), 161-168, 2003 | 97 | 2003 |
| Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: the Hepatitis Delta International Network (HDIN) A Wranke, LM Pinheiro Borzacov, R Parana, C Lobato, S Hamid, ... Liver International 38 (5), 842-850, 2018 | 94 | 2018 |
| The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other … PA Papamichalis, K Zachou, GK Koukoulis, A Veloni, EG Karacosta, ... Journal of autoimmune diseases 4, 1-12, 2007 | 86 | 2007 |
| DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B GV Papatheodoridis, EI Rigopoulou, M Papatheodoridi, K Zachou, ... Antiviral Therapy 23 (8), 677-685, 2018 | 83 | 2018 |
| Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease NK Gatselis, K Zachou, GL Norman, S Gabeta, P Papamichalis, ... Autoimmunity 46 (7), 471-479, 2013 | 81 | 2013 |
| Occult hepatitis B virus infection in patients with autoimmune liver diseases SP Georgiadou, K Zachou, C Liaskos, S Gabeta, EI Rigopoulou, ... Liver International 29 (3), 434-442, 2009 | 78 | 2009 |
